To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

NCT04551053 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

177

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated due to futility.

Conditions

Myelofibrosis
Primary Myelofibrosis
Post Essential Thrombocythemia Myelofibrosis
Post Polycythemia Vera Myelofibrosis

Interventions

DRUG: parsaclisib
DRUG: ruxolitinib
DRUG: placebo

Sponsor

Incyte Corporation